Cash, cash equivalents, and marketable securities totaled $539 million as of June 30, 2025, including $80 million raised through an ATM facility.
Crysvita contributed $120 million in Q2 2025, with $79 million from North America, $35 million from Latin America and Turkey, and $7 million from Europe.
Dojolvi generated $23 million, Evkeeza $15 million, and Mepsevii $8 million in Q2 2025, all showing steady growth.
Net cash used in operations was $108 million for Q2 and $275 million for the first half of 2025.
Net loss for the quarter was $115 million or $1.17 per share.
Total operating expenses were $274 million, including $165 million in R&D, $87 million in SG&A, and $23 million in cost of sales, with $39 million in noncash stock-based compensation.
Ultragenyx reported total revenue of $166 million in Q2 2025, a 13% increase over Q2 2024, and 20% growth for the first half of 2025 compared to the same period in 2024.